Dr Carolyn Luscombe, Head of Research and Development, has received an award at the HIV DART and Emerging Viruses 2018 in Miami, Florida for the presentation entitled
“BIT225-009: Significant Immunological Outcomes after 12 weeks of BIT225 and Antiretroviral Therapy in an HIV-1 Phase 2 Clinical Trial”.
The award is an acknowledgment of the importance of the outcomes from the Phase 2 trial data presented, as well as the robustness of the science underlying the Company’s programs.
DYOR
BIT won an award due to the presentation
Add BIT (ASX) to my watchlist
 (20min delay)
|
|||||
|
Last
1.9¢ |
Change
0.000(0.00%) |
Mkt cap ! $17.14M | |||
| Open | High | Low | Value | Volume |
| 1.9¢ | 2.0¢ | 1.9¢ | $6.369K | 330.6K |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 2 | 847148 | 1.9¢ |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| 2.0¢ | 1129029 | 5 |
View Market Depth
| Last trade - 16.10pm 30/09/2024 (20 minute delay) ? |
| BIT (ASX) Chart |